INS and metabolic dysfunction-associated steatotic liver disease: In humans, insulin has attracted particular attention as several lines of evidence suggest that insulin, acting through the insulin receptor, stimulates de novo lipogenesis sufficiently to make a major contribution to liver fat accumulation in NAFLD (48–50).